Emmes
Emmes is a global full-service clinical research organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation. With over 47 years of experience, Emmes has conducted more than 2,150 clinical trials across various therapeutic areas, including vaccines and infectious diseases, ophthalmology, neurology, rare diseases, and cell & gene therapies. The company leverages technology and AI to enhance clinical research efficiency and quality, aiming to improve patient outcomes and accelerate the delivery of new treatments.
Emmes
401 N. Washington Street, Suite 700, Rockville, MARYLAND 20850, UNITED STATES
What We Do
Clinical Research Services
Emmes offers a robust suite of services for Phase I-IV clinical trials, registries, observational studies, and other clinical research, including statistical design and analysis, protocol development, and data management.
Biostatistics
Emmes provides strong biostatistical support essential for the design and execution of efficient, high-quality clinical trials, optimizing study design and performance through advanced statistical approaches.
Clinical Data Management
Emmes collaborates with clients to define, collect, manage, and analyze quality data that supports product development and public health ambitions.
Pharmacovigilance and Medical Monitoring
Emmes ensures patient safety and manages clinical trial safety risks through dedicated pharmacovigilance services and medical monitoring.
Global Regulatory Affairs
Emmes helps navigate the regulatory pathways for investigational new drugs, devices, and biologics, providing proactive guidance to mitigate development risks.
Endpoint Solutions
Emmes transforms patient engagement in clinical trials by developing novel outcome measures and utilizing remote data collection methods.
Key People
Adam Mendizabal, Ph.D.
Senior Vice President & TA Lead, Cell & Gene Therapy
Jose Jimeno
Chief Executive Officer & TA Lead, Vaccines & Infectious Diseases
Steffanie Wilson
Vice President & TA Lead, Neuroscience
Matt Bond
Chief Financial Officer
Jeff Ramage
Chief Legal Officer
News & Updates
Emmes awarded multi-task, IDIQ contract with $50M ceiling, to support NIDA’s clinical trials network
Emmes has been awarded a contract to support the National Institute on Drug Abuse's Clinical Trials Network, continuing its long-standing partnership with the NIH.
The acquisition of VaxTRIALS enhances Emmes' capabilities in vaccine research across Latin America.
Emmes announced the creation of the Emmes Group, which will include a new business unit, Veridix AI, focused on embedding technology and AI in clinical operations.
Emmes Endpoint Solutions has submitted a qualification plan to the FDA for a novel video assessment tool for Duchenne muscular dystrophy.
98% Client retention rate
Emmes has maintained a 98% client retention rate, showcasing its commitment to client satisfaction and service quality.
2,150+ Clinical trials conducted
Emmes has successfully conducted over 2,150 clinical trials in more than 90 countries, demonstrating its global reach and expertise.